Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.83 |
| ▸ | BRAF | P15056 | 8/20 | 0.83 |
| ▸ | ABL1 | P00519 | 5/20 | 0.83 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.83 |
| ▸ | AXL | P30530 | 2/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | PLK4 | O00444 | 1/20 | 0.83 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.83 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.83 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.83 |
| ▸ | JAK2 | O60674 | 1/20 | 0.83 |
| ▸ | ERN1 | O75460 | 1/20 | 0.83 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.83 |
| ▸ | STK10 | O94804 | 1/20 | 0.83 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.83 |
| ▸ | RAF1 | P04049 | 1/20 | 0.83 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.83 |
| ▸ | LCK | P06239 | 1/20 | 0.83 |
| ▸ | FYN | P06241 | 1/20 | 0.83 |
| ▸ | CDK1 | P06493 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078838 | 0.93 | BRAF (0.83) | MAPK14BRAFABL1RIPK1AXL | |
| Hydrochloric Acid SCHEMBL2031193 | 0.92 | BRAF (0.82) | MAPK14BRAFABL1RIPK1AXL | |
| Rebastinib SCHEMBL29354367 | 0.91 | BRAF (1.00) | MAPK14BRAFABL1RIPK1AXL | |
| Rebastinib SCHEMBL2034290 | 0.91 | BRAF (1.00) | MAPK14BRAFABL1RIPK1AXL | |
| Rebastinib SCHEMBL30499050 | 0.91 | BRAF (1.00) | MAPK14BRAFABL1RIPK1AXL | |
| Rebastinib SCHEMBL29733447 | 0.91 | BRAF (1.00) | MAPK14BRAFABL1RIPK1AXL | |
| SCHEMBL18804584 | 0.91 | BRAF (0.86) | MAPK14BRAFABL1RIPK1AXL | |
| Rebastinib SCHEMBL29733460 | 0.90 | BRAF (0.99) | MAPK14BRAFABL1RIPK1AXL | |
| Rebastinib SCHEMBL2026623 | 0.90 | BRAF (0.99) | MAPK14BRAFABL1RIPK1AXL | |
| SCHEMBL2081819 | 0.90 | BRAF (0.76) | MAPK14BRAFABL1RIPK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013036232-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | MAPK14 323/4885BRAF 5/4885ABL1 1/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | MAPK14 354/4885BRAF 115/4885ABL1 81/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | MAPK14 354/4885BRAF 115/4885ABL1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.